Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Equities, Inc. tumbled roughly 9% to $41.40 on Tuesday, hitting a session low of $39.52, as investors reacted to the company’s first-quarter results. Though the life-science landlord reported a sizable accounting profit, underlying operating trends proved softer than expected, according to market data.

Biotechnology · Earnings Reports · NYSE:ARE · Real Estate · Stock Market
Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

Intellia Therapeutics on Monday reported its experimental CRISPR gene-editing therapy led to a significant reduction in swelling attacks in a late-stage hereditary angioedema study. The company has started a rolling submission for U.S. approval of the drug, called lonvoguran ziclumeran, or lonvo-z. Designed as an outpatient infusion, lonvo-z targets a rare disorder that triggers severe swelling in areas like the face, airway, abdomen, and limbs.
27 April 2026
·
Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics is slated to release top-line results Monday from HAELO, its pivotal trial of lonvoguran ziclumeran—an experimental, one-and-done therapy aimed at hereditary angioedema. The company bills this as the first-ever Phase 3 data for an in vivo CRISPR gene-editing therapy, meaning the genetic tweak happens directly in the patient rather than in lab-modified cells.
25 April 2026
···
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics Inc. is heading into a heavy clinical-data stretch with fresh Wall Street backing, after Stifel analyst Paul Matteis initiated coverage of the Nasdaq-listed company with a Buy rating and a $30 price target. The focus is DT120 ODT, an orally disintegrating tablet form of lysergide D-tartrate, better known as LSD, now in late-stage trials for anxiety and depression.
18 April 2026
··
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Shares of Eli Lilly and Company jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slump and pulling ahead of a broader market that dropped. The S&P 500 slipped 0.43%, while the Dow lost 1.05%, as traders grappled with stretched valuations and renewed jitters over the speed of artificial intelligence’s impact on market leaders and laggards.
28 February 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares slipped 1.2% to $35.80 in early premarket moves Tuesday, following a 5.7% jump to $36.23 at Monday’s close. Wolfe Research kicked off its coverage with an “Outperform” and tagged a $40 price target. The stock remains below its 52-week peak of $38.69, while roughly 21.6% of the float is sold short, according to MarketBeat.
24 February 2026
···
1 … 5 6 7 8 9 … 22
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

82/100
View full portfolio
Editorial model selection. Not personalised advice.